Citations

Clear

1893 citation(s) found for "Wu, Kenneth".

Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G. , Usmani, Saad Zafar, Bensinger, William, Dubin, Franck , Liu, Qianying , Vitse, Olivier , Mıkhael, Joseph , Richardson, Paul Gerard Guy , Usmani, Saad Zafar, Raje, Noopur , Anderson, Kenneth C.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8038-8038

10.1200/jco.2018.36.15_suppl.8038 Get It

Examining patients’ medical and psychosocial experiences following detection of a CDH1 variant with multiplex genetic testing.
Brandt, Amanda , Brower, Jamie , Symecko, Heather , Offit, Kenneth , Hamilton, Jada G. , Long, Jessica M. , Salo‐Mullen, Erin E. , Christian, Stephanie N. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1583-1583

10.1200/jco.2018.36.15_suppl.1583 Get It

Prospective Registry of Multiplex Testing (PROMPT): Feasible and sustainable.
Symecko, Heather , Brower, Jamie , Drogan, Christine , Harstad, Tricia, Pradhan, Nisha , Walsh, Michael F. , Offit, Kenneth , Salo‐Mullen, Erin E. , Hamilton, Jada G. , Balmañà, Judith , Couch, Fergus J. , Garber, Judy E. , Domchek, Susan M. , Robson, Mark E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1543-1543

10.1200/jco.2018.36.15_suppl.1543 Get It

Minimum Clinically Important Difference: Current Trends in the Orthopaedic Literature, Part II: Lower Extremity
Copay, Anne G. , Eyberg, Blake , Chung, Andrew S. , Zurcher, Kenneth S. , Chutkan, Norman , Spangehl, Mark J. , Zurcher, Kenneth , Chung, Andrew , Spangehl, Mark

Mayo Clinic

JBJS Reviews | August 31, 2018 | Volume: 6 | Issue: 9 | Pages: e2-e2

10.2106/jbjs.rvw.17.00160 | PMID 30179898 Get It

Background: The minimum clinically important difference (MCID) attempts to define the patient’s experience of treatment outcomes. Efforts at calculating the MCID have yielded multiple and inconsistent MCID values. The purposes of this review were to describe the usage of the MCID in the most recent orthopaedic literature, to explain the limitations of its current uses, and to clarify the underpinnings of the MCID calculation, so as to help practitioners to understand and utilize the MCID and to guide future efforts to calculate the MCID. In Part I of this review, we sampled the orthopaedic literature in relation to the upper extremity. In this part, Part II, of the review, we will focus on the lower-extremity literature. Methods: A review was conducted of the 2014 to 2016 MCID-related publications in The Journal of Arthroplasty, The Journal of Bone & Joint Surgery, The American Journal of Sports Medicine, Foot & Ankle International, Journal of Orthopaedic Trauma, Journal of Pediatric Orthopaedics, and Journal of Shoulder and Elbow Surgery. Only clinical science articles utilizing patient-reported outcome measures (PROMs) were included in the analysis. A keyword search was then performed to identify articles that used the MCID. Articles were then further categorized into upper-extremity and lower-extremity publications. The MCID utilization in the selected articles was characterized and was recorded. Results: The MCID was referenced in 129 (7.5%) of 1,709 clinical science articles that utilized PROMs: 79 (61.2%) of the 129 articles were related to the lower extremity; of these, 11 (13.9%) independently calculated the MCID values and 68 (86.1%) used previously published MCID values as a gauge of their own results. The MCID values were calculated or were considered for 31 PROMs, of which 24 were specific to the lower extremity. Eleven different methods were used to calculate the MCID. The MCID had a wide range of values for the same questionnaires, for instance, 5.8 to 31.3 points for the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Conclusions: There are more than twice as many PROMs for the lower extremity (24) than for the upper extremity (11), confirming that the determination of useful MCID values is, in part, hampered by the proliferation of PROMs in the field of orthopaedics. The difference between significance and clinical importance needs to be further clarified. For instance, the common use of determining sample size with the MCID and comparing group means with the MCID implies that a significant result will also be clinically important. Further, the study of the MCID would benefit from consensus agreement on relevant terminology and the appropriate usage of the MCID determining equations. Clinical Relevance: MCID is increasingly used as a measure of patients’ improvement. However, MCID does not yet adequately capture the clinical importance of patients’ improvement.
Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs
Whitfield, Kyly C. , Adamolekun, Bola, Bergeron, Gilles, Brown, Kenneth H. , Cox, Lorna, Fattal‐Valevski, Aviva , Frank, Elizabeth L., Hiffler, Laurent , Hlaing, Lwin Mar , Kapner, Hallie, Mousavi, Maral P. S. , Roth, Daniel , Tsaloglou, Maria‐Nefeli , Wieringa, Frank T. , Combs, Gerald F., Fischer, Philip R. , Bourassa, Megan W. , Bettendorff, Lucien , Jefferds, Maria Elena , Kounnavong, Sengchanh

Mayo Clinic

Annals of the New York Academy of Sciences | August 28, 2018 | Volume: 1430 | Issue: 1 | Pages: 3-43

10.1111/nyas.13919 | PMID 30151974 Get It

AbstractThiamine is an essential micronutrient that plays a key role in energy metabolism. Many populations worldwide may be at risk of clinical or subclinical thiamine deficiencies, due to famine, reliance on staple crops with low thiamine content, or food preparation practices, such as milling grains and washing milled rice. Clinical manifestations of thiamine deficiency are variable; this, along with the lack of a readily accessible and widely agreed upon biomarker of thiamine status, complicates efforts to diagnose thiamine deficiency and assess its global prevalence. Strategies to identify regions at risk of thiamine deficiency through proxy measures, such as analysis of food balance sheet data and month‐specific infant mortality rates, may be valuable for understanding the scope of thiamine deficiency. Urgent public health responses are warranted in high‐risk regions, considering the contribution of thiamine deficiency to infant mortality and research suggesting that even subclinical thiamine deficiency in childhood may have lifelong neurodevelopmental consequences. Food fortification and maternal and/or infant thiamine supplementation have proven effective in raising thiamine status and reducing the incidence of infantile beriberi in regions where thiamine deficiency is prevalent, but trial data are limited. Efforts to determine culturally and environmentally appropriate food vehicles for thiamine fortification are ongoing.
Focused Cardiac Ultrasonography: Current Applications and Future Directions
Luong, Christina , Ong, Kevin , Kaila, Kendeep, Pellikka, Patricia A. , Gin, Kenneth, Tsang, Teresa S.M. , Pellikka, Patricia A

Mayo Clinic

Journal of Ultrasound in Medicine | August 28, 2018 | Volume: 38 | Issue: 4 | Pages: 865-876

10.1002/jum.14773 | PMID 30146784 Get It

Focused cardiac ultrasonography is performed by clinicians at the bedside and is used in time‐sensitive scenarios to evaluate a patient's cardiovascular status when comprehensive echocardiography is not immediately available. This simplified cardiac ultrasonography is often performed by noncardiologists using small, portable devices to augment the physical examination, triage patients, and direct management in both critical care and outpatient settings. However, as the use of focused cardiac ultrasonography continues to expand, careful consideration is required regarding training, scope of practice, impact on patient outcomes, and medicolegal implications. In this review, we examine some of the challenges with rapid uptake of this technique and explore the benefits and potential risk of focused cardiac ultrasonography. We propose possible mechanisms for cross‐specialty collaboration, quality improvement, and oversight.
Movement disorder society criteria for clinically established early Parkinson's disease
Berg, Daniela , Adler, Charles H. , Bloem, Bastiaan R. , Gasser, Thomas , Halliday, Glenda M. , Lang, Anthony E. , Lewis, Simon J.G. , Li, Yuan , Liepelt‐Scarfone, Inga , Marek, Kenneth , Maetzler, Corina , Mi, Taomian, Oertel, Wolfgang H. , Olanow, C. Warren , Ríos‐Romenets, Silvia, Schäffer, Eva, Seppi, Klaus , Heim, Beatrice , Slow, Elizabeth , Bledsoe, Ian O. , Deuschl, Günther , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Adler, C H , Lewis, Simon J G , Seppi, Klaus , Heim, Beatrice , Chan, Piu , Goetz, Christopher G. , Litvan, Irene , Obeso, Jose Angel , Poewe, Werner H , Stern, Matthew , Postuma, Ronald B.

Mayo Clinic

Movement Disorders | August 26, 2018 | Volume: 33 | Issue: 10 | Pages: 1643-1646

10.1002/mds.27431 | PMID 30145841 Get It

ABSTRACTBackground: In 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies suggest high accuracy, one unmet need is for highly specific criteria for clinical trials in early/de novo PD.Objectives: The objective of this study was to generate and test a PD diagnostic criteria termed “clinically established early PD.”Methods: We modified the Movement Disorder Society criteria to increase specificity for early PD by removing all disease duration components and changing red flags to absolute exclusions. We then estimated the sensitivity/specificity of clinically established early PD criteria in patients with disease duration <5 years, selected from a 626‐patient validation study.Results: After documentation of parkinsonism, 18 individual exclusion criteria are assessed that preclude the diagnosis of “clinically established early PD.” Among 212 PD and 152 non‐PD patients, the estimated specificity was 95.4%, with 69.8% sensitivity.Conclusions: We describe high‐specificity criteria for de novo PD, which are freely available for use in clinical trials. © 2018 International Parkinson and Movement Disorder Society
The Turnover in Normal Dogs of Prothrombin and Its Fragments; Effect of Induced Intravascular Coagulation
Owen, Charles A., Mann, Kenneth G. , McDuffie, Frederic C.

Mayo Clinic

Thrombosis and Haemostasis | August 23, 2018 | Volume: 42 | Issue: 02 | Pages: 548-555

10.1055/s-0038-1666892 Get It

SummaryWhen 125I-labeled canine prothrombin was given to normal adult dogs intravenously, it was calculated that 240% of the plasma prothrombin crossed the capillary barrier per day, 410% of the interstitial prothrombin returned to the blood stream daily, and 79% of the plasmatic prothrombin was catabolized per day. These data are in close agreement with those observed for bovine prothrombin in calves by Takeda (1970).When derived from normal dog prothrombin, prethrombin-1 is a mixture of 2 polypeptides, one larger than the other, and both present in about equal amounts. The longer peptide, “prethrombin-1-long,” was catabolized twice as fast as prothrombin, and the shorter, “prethrombin-1-short,” 4 times faster. Prothrombin fragment-1 was catabolized by the normal dog still more rapidly.The catabolism of prothrombin was not accelerated in 3 dogs receiving continuous infusions of a thromboplastic emulsion of dog brain. Nor was the level of prothrombin in their plasma remarkably altered.
Gastrointestinal: Caval tumor thrombus and duodenal metastasis from endometrial carcinoma
Huynh, Kenneth N. , Wu, KJ, Nguyen, Ba D.

Mayo Clinic

Journal of Gastroenterology and Hepatology | August 23, 2018 | Volume: 34 | Issue: 2 | Pages: 309-309

10.1111/jgh.14411 | PMID 30136307 Get It